

肺炎炎	0	0	1 (0.4%)
泌尿生殖器閉塞-尿管	1 (0.4%)	0	0
泌尿生殖器狭窄-尿管	1 (0.4%)	0	0
血栓症/血栓/塞栓	2 (0.9%)	1 (0.4%)	0
GGT	1 (0.4%)	0	0
アミラーゼ	1 (0.4%)	0	0
リンパ嚢腫	0	1 (0.4%)	0
浮腫-四肢	0	1 (0.4%)	0

有害事象名	Grade2 以上		
	AP 群 n=230 (%)	DP 群 n=224 (%)	TC 群 n=227 (%)
神経障害・知覚性	7 (3.0%)	18 (8.0%)	68 (30.0%)
神経障害・運動性	3 (1.3%)	3 (1.3%)	19 (8.4%)

## 2) 薬剤の投与量を変更した症例 集計表

(対象症例: Form D が少なくとも 2 サイクル分回収されている 642 症例)

(1 症例に対し変更理由および変更回数複数あり)

### 【AP 群】 n=220 例

#### ADM 投与量減量理由

変更理由	
発熱性好中球減少	32
G4 好中球減少 5 日間	26
G3 以上の非血液学的毒性	9
その他*	4
不明/問い合わせ中	2

\*: 水腎症

Grade4 の血小板減少を認め主治医の判断で減量  
好中球数減少症(Grade4)とサイクル遅延  
貧血

#### CDDP 投与量減量理由

変更理由	
発熱性好中球減少	2
G4 好中球減少 5 日間	1
G3 以上の非血液学的毒性	9
血清クレアチニン	3
その他*	6
不明/問い合わせ中	1

\*: 37°C 台の熱

水腎症

Grade4 の血小板減少を認め主治医の判断で減量

Grade3 の食欲不振、疲労の持続

貧血

Serum Cr:0.9 (Cr:46)

【DP 群】 n=212 例

DOC 投与量減量理由

変更理由	
発熱性好中球減少	9
G4 好中球減少 5 日間	16
G3 以上の非血液学的毒性	15
その他*	2
不明/問い合わせ中	3

\*: Dehydration Grade3(2 症例)

CDDP 投与量減量理由

変更理由	
発熱性好中球減少	1
血清クレアチニン	5
G3 以上の非血液学的毒性	13
その他	0
不明/問い合わせ中	4

【TC 群】 n=210 例

PTX 投与量減量理由

変更理由	
発熱性好中球減少	2
G4 好中球減少 5 日間	1
G2 以上の末梢神経障害	29
G3 以上の非血液学的毒性	17
G3 以上の血小板減少	1
その他*	6
不明/問い合わせ中	0

\*: P.S.  $\geq$  3

Infection

アレルギー反応

基準内だが副作用強く減量した

関節痛

Grade4 Neutropenia 後 G-CSF うつも ANC がなかなか上がらなかったため減量が必要と考えた。

CBDCA 投与量減量理由

変更理由	
G3 以上の血小板減少	20
G3 以上の非血液学的毒性	18
その他*	5
不明/問い合わせ中	0

\* P.S.  $\geq$  3

Infection

アレルギー反応

基準内だが副作用強く減量した

医師の判断(初回クレアチニン値が特に低かったため)

3) 投与を延期した症例集計表(投与延期とは、+3日を超えて延期されているもの)  
 (対象症例:Form D が少なくとも2サイクル分回収されている642症例)

1症例に対し延期回数 複数あり

コース	血液毒性			肝・腎障害			神経障害			その他の有害事象			有害事象以外			対象症例		
	AP	DP	TC	AP	DP	TC	AP	DP	TC	AP	DP	TC	AP	DP	TC	AP	DP	TC
1→2	42	6	25	1	0	1	0	1	1	11	9	7	12	13	18	220	212	210
2→3	54	10	44	0	0	0	0	0	1	7	6	2	18	14	20	207	200	192
3→4	61	5	36	0	1	0	0	0	3	8	6	6	15	14	15	189	192	186
4→5	58	11	51	0	0	0	0	0	1	11	2	5	14	18	15	176	178	171
5→6	61	11	49	1	2	2	0	0	0	9	3	7	13	12	13	162	169	156

7. プロトコル逸脱/逸脱の可能性のある症例一覧

今回報告分

症例番号	内容	備考	モニタリング委員会判断
1) 減量規準・延期規準などが守られていない症例			
309	3サイクルにおいて Febrile Neutropenia の Grade3、Infection Grade3 が発現しているが、次サイクルの薬剤がいずれも減量されていない	AP 群/関西ろうさい病院	逸脱(解析対象)
390	2サイクルにおいて ALT 上昇の Grade3 が発現しているが、次サイクルの薬剤がいずれも減量されていない	DP 群/産業医科大学	逸脱(解析対象)
512	3サイクルにおいて、Infection with normal ANC or grade 1 or 2 neutropenia の Grade3 が発現しているが、次サイクルの薬剤がいずれも減量されていない	TC群/都立駒込病院	逸脱(解析対象)
742	1-2サイクルにおいて、Infection with grade 3 or 4 neutropenia の Grade3 が発現しているが、次サイクルの薬剤がいずれも減量されていない	AP 群/九州がんセンター	逸脱(解析対象)
512	2-6サイクルにおいて Neuropathy/Sensory の Grade2 が発現しているが、いずれのサイクルも PTX が減量されていない	TC群/都立駒込病院	逸脱(解析対象)
618	1-6サイクルにおいて Neuropathy/Sensory&Motor の Grade2-3 が発現しているが、いずれのサイクルも PTX が減量されていない	TC群/高知医療センター	逸脱(解析対象)
649	5サイクルにおいて Neuropathy/Sensory の Grade2 が発現しているが、次サイクルの PTX が減量されていない	TC群/新潟県立がんセンター	逸脱(解析対象)
697	1サイクルにおいて	TC群/大阪府立	逸脱(解析対象)

	Neuropathy/Sensory の Grade2 が発現しているが、次サイクルの PTX が減量されていない	成人病	
024	4-5 サイクルにおいて PLT ↓ Grade3 が発現しているが、次サイクルの CBDCA が減量されていない	TC 群/関西ろうさい病院	逸脱(解析対象)
症例番号	内容	備考	モニタリング委員会判断
ii) 検査値等の欠測症例			
637	6 サイクルにおいて生化学検査全てが未実施	TC 群/新潟県立がんセンター	逸脱(解析対象)
症例番号	内容	備考	モニタリング委員会判断
iii) 体重補正の未実施			
559	6 サイクルにおいて体重が <sup>g</sup> +5kg を超えて増加していたが、体重の補正がなされていない	TC 群/呉医療センター	逸脱(解析対象)
576	6 サイクルにおいて体重が <sup>g</sup> +5kg を超えて増加していたが、体重の補正がなされていない	DP 群/琉球大学	逸脱(解析対象)
682	6 サイクルにおいて体重が <sup>g</sup> -5kg を超えて減少していたが、体重の補正がなされていない	DP 群/新潟大学	逸脱(解析対象)
症例番号	内容	備考	モニタリング委員会判断
iv) その他			
662	1 サイクルの投与が登録の 14 日後 (GW をはさんだため & 主治医の都合)	AP 群/愛知県がんセンター	逸脱(解析対象)
697	3 サイクルの投与が 2 サイクルの 43 日後 (Neuropathy ≥ Grade2 のため)	TC 群/大阪府立成人病	逸脱(解析対象)
692	症例登録時の年齢の記載に誤りがあったため、CBDCA の投与量が規準投与量より外れた (1 サイクルのみ CBDCA 投与量が 703mg/body のところ 849mg/body)	TC 群/九州医療センター	逸脱(解析対象)
744	Grade3 で登録したが、Grade2 であった	AP 群/北里大学	逸脱(解析対象)
210	5 サイクル開始前の ANC: 1439 にて投与が開始された	AP 群/岩手医科大学	逸脱(解析対象)

前回までの逸脱も合わせた集計

	AP 群	DP 群	TC 群
減量規準の不遵守			
1) 発熱性好中球減少が発現するも減量せず	4	1	0
2) grade4 好中球 ↓ 5 日以上持続するも減量せず	0	0	0
3) grade3 以上の非血液毒性発現するも減量せず	6	8	11
4) CRTN > 1.2 で CCr < 50 発現するも減量せず	0	0	-
5) grade2 以上の末梢神経障害発現するも減量せず	-	-	21
6) grade3 以上の血小板減少発現するも減量せず	-	-	9
体重補正忘れ	11	10	13
検査値等の欠測	5	3	8
登録後に割付調整因子の誤りが発覚	3	1	2
その他	12	6	16

8. 外科的切除術の内容

4. 治療前背景因子で報告済み

9. 生存期間

試験実施中のため、公開情報はなし

10. その他、試験の進捗や安全性に関する問題点

CRF(症例報告書)回収状況

患者背景回収率: 90.0% (登録から1ヶ月以内に「B」「P」「S」「F」Form が回収された割合)

治療状況回収率: 89.2% (プロトコール治療がしており、「D」「T」Form が全て回収された割合)

追跡調査回収率: 56.9% (2010年9月に実施 対象 640 症例)

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N; Japan Society of Gynecologic Oncology	Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition	Int J Clin Oncol	15	531-542	2010
Kisu I, Banno K, Kobayashi Y, Ono A, Masuda K, Ueki A, Nomura H, Hirasawa A, Abe T, Kouyama K, Susumu N, Aoki D	Flexible hysteroscopy with narrow band imaging (NBI) for endoscopic diagnosis of malignant endometrial lesions	Int J Oncol	38	613-618	2011
Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N	Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)	Ann Oncol	22	636-642	2011
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N	Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis	Lancet	375	1165-1172	2010
Konno Y, Todo Y, Minobe S, Kato H, Okamoto K, Sudo S, Takeda M, Watari	A retrospective analysis of postoperative complications with or without para-aortic	Int J Gynecol Cancer	21	385-390	2011

H, Kaneuchi M, Sakuragi N	lymphadenectomy in endometrial cancer				
Takano M, Kikuchi Y, Asakawa T, Goto T, Kita T, Kudoh K, Kigawa J, Sakuragi N, Sakamoto M, Sugiyama T, Yaegashi N, Tsuda H, Seto H, Shiwa M	Identification of potential serum markers for endometrial cancer using protein expression profiling	J Cancer Res Clin Oncol	136	475-481	2010
大原 樹, 小林陽一, 鈴木直, 木口一成, 新井正秀, 角田新平, 上坊敏子, 平澤 猛, 村松俊成, 三上幹男	子宮内膜間質肉腫 18 例の臨床病理学的検討	日本婦人科腫瘍学会雑誌	28	144-149	2010
Ferdousi J, Nagai Y, Asato T, Hirakawa M, Inamine M, Kudaka W, Kariya K, Aoki Y	Impact of human papillomavirus genotype on response to treatment and survival in patients receiving radiotherapy for squamous cell carcinoma of the cervix	Exp Ther Med	1	525-530	2010
Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K	Prolonged long-term survival of low grade endometrial stromal sarcoma (LGESS) patients with lung metastasis following treatment with medroxyprogesterone acetate (MPA)	Int J Clin Oncol	15	179-183	2010
Nakayama K, Nagai Y, Ishikawa M, Aoki Y, Miyazaki K	Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stage III and IV endometrial cancer	Int J Clin Oncol	15	440-446	2010
平川 誠, 久高 亘, 稲嶺盛彦, 長井 裕, 青木陽一	子宮体癌治療の厳しさ 子宮体部類内膜腺癌 G3、漿液性腺癌、明細胞腺癌の臨床背景と治療予後	日本婦人科腫瘍学会誌	28	138-143	2010
平川 誠, 長井 裕, 青木陽一	子宮体癌の特殊な組織型への対応 明細胞癌, 漿液性癌, 癌肉腫	臨床婦人科産科	64	1656-1661	2010
寒河江 悟	クリニカルカンファレンス; 婦人科癌進行期分類の間	日産婦誌	62	N-211-	2010

	題点			N-216	
寒河江 悟	FIGO 進行期分類改訂の経緯 Current Organ Topics: Gynecologic Cancer 婦人科が ん 婦人科がんの新しいス テージング	癌と化学療法	38	203-206	2011
委員長: 寒河江 悟 他 (GCIG 委員会編集)	GCIG だより 2010 年総集号 婦人科悪性 腫瘍化学療法研究機構	JGOG web site	6		2011
Watanabe Y, Satou T, Nakai H, Etoh T, Dote K, Fujinami N, Hoshiai H	Evaluation of parametrial spread in endometrial carcinoma	Obstet Gynecol	116	1027-1034	2010
Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D, Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I, Yoshikawa H	Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection	J Clin Oncol	28	1727-1732	2010
Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H, Kamura T	A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)	Jpn J Clin Oncol	40	90-93	2010
Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M	A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer	Jpn J Clin Oncol	41	278-282	2011
Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K	Multicenter, phase II, placebo-controlled, double-blind, randomized study	Cancer Sci,	101	2455-2461	2010



	of aprepitant in Japanese patients receiving high-dose cisplatin				
Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y	Clinical characteristics and outcomes of women with stage IV endometrial cancer	Med Oncol	27	1371-1377	2010

## Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition

Satoru Nagase · Hidetaka Katabuchi · Masamichi Hiura · Noriaki Sakuragi · Yoichi Aoki · Junzo Kigawa · Tsuyoshi Saito · Toru Hachisuga · Kiyoshi Ito · Takashi Uno · Noriyuki Katsumata · Shinichi Komiya · Nobuyuki Susumu · Makoto Emoto · Hiroaki Kobayashi · Hirohito Metoki · Ikuro Konishi · Kazunori Ochiai · Mikio Mikami · Toru Sugiyama · Makio Mukai · Satoru Sagae · Hiroshi Hoshiai · Daisuke Aoki · Masahide Ohmichi · Hiroyuki Yoshikawa · Tsuyoshi Iwasaka · Yasuhiro Udagawa · Nobuo Yaegashi

Received: 30 August 2010 / Published online: 11 November 2010  
© Japan Society of Clinical Oncology 2010

**Abstract** Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently. Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed. Additionally, it remains controversial whether full nodal staging is required in all

patients. Furthermore, adjuvant therapy differs between Japan and Western countries. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 and revised in 2009. The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example

S. Nagase (✉) · K. Ito · H. Metoki · N. Yaegashi  
Department of Obstetrics and Gynecology,  
Tohoku University Graduate School of Medicine,  
1-1 Seiryō-machi, Aoba-ku, Sendai 980-8574, Japan  
e-mail: nagases@med.tohoku.ac.jp

H. Katabuchi  
Department of Obstetrics and Gynecology,  
Faculty of Life Science,  
Kumamoto University School of Medicine,  
Kumamoto, Japan

M. Hiura  
Department of Gynecology, Shikoku Cancer Center,  
Matsuyama, Ehime, Japan

N. Sakuragi  
Department of Obstetrics and Gynecology, Hokkaido University  
Graduate School of Medicine, Sapporo, Japan

Y. Aoki  
Department of Obstetrics and Gynecology,  
Faculty of Medicine, University of the Ryukyus,  
Nishihara, Okinawa, Japan

J. Kigawa  
Department of Obstetrics and Gynecology,  
Tottori University School of Medicine, Yonago, Japan

T. Saito  
Department of Obstetrics and Gynecology,  
Sapporo Medical University, Sapporo, Japan

T. Hachisuga  
Department of Obstetrics and Gynecology,  
University of Occupational and Environmental Health School  
of Medicine, Kitakyūsu, Japan

T. Uno  
Department of Radiology,  
Chiba University Graduate School of Medicine, Chiba, Japan

N. Katsumata  
Department of Medical Oncology, National Cancer Center,  
Tokyo, Japan

S. Komiya · Y. Udagawa  
Department of Obstetrics and Gynecology,  
Fujita Health University School of Medicine,  
Toyoake, Aichi, Japan

N. Susumu · D. Aoki  
Department of Obstetrics and Gynecology,  
Keio University School of Medicine, Tokyo, Japan

M. Emoto  
Department of Obstetrics and Gynecology,  
Fukuoka University School of Medicine, Fukuoka, Japan

H. Kobayashi  
Department of Obstetrics and Gynecology,  
Kyūsu University Graduate School of Medicine,  
Fukuoka, Japan

leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma. These guidelines are composed of nine chapters and include nine algorithms. The guidelines also contain fifty-one clinical questions (CQs) and each CQ consists of recommendations, background, explanations, and references. The treatment recommendations herein are tailored to reflect current Japanese clinical practice and ensure equitable care for all Japanese women diagnosed with endometrial cancer.

**Keywords** Endometrial cancer · Clinical practice guidelines · Surgery · Chemotherapy · Irradiation

## Introduction

Endometrial carcinoma is one of the most common malignancies of the female genital tract. In Japan, the age-adjusted incidence rate of endometrial cancer was 6.5 (per 100,000 women) in 2004, indicative of a four to fivefold increase over the last three decades [1]. To treat endometrial cancer, surgery, chemotherapy, radiation, and hormone therapy are used either alone or sequentially. Surgery is the cornerstone of the management of patients with endometrial cancer. When the disease is limited to the uterus, hysterectomy and bilateral salpingo-oophorectomy, and pelvic/para-aortic lymph node dissection are recommended by The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology [2]. There is, however, significant variability with regard to the type of hysterectomy performed for endometrial cancer in Japan [3]. Additionally, it remains controversial whether all patients require full nodal staging [4, 5].

Furthermore, there are differences with regard to the adjuvant therapies employed in Japan and in Western countries. In Western countries, radiotherapy is the mainstay of postoperative adjuvant therapy whereas in Japan it is more frequently chemotherapy. These differences are one reason why evidence from Western countries cannot be applied directly to developing recommendations for Japanese patients. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 for the first time, and revised in 2009. The revision contains two new sections. The first is a chapter addressing the treatment of mesenchymal tumors, for example leiomyosarcoma. The second is a section addressing the treatment of serous and clear-cell adenocarcinoma. The treatment recommendations herein are tailored to reflect current Japanese clinical practices and ensure equitable care for all Japanese women diagnosed with endometrial cancer.

## Basic policies in creating the guidelines

To create these guidelines, the Guidelines Formulation Committee and Evaluation Committee were independently established within the Committee for Treatment Guidelines for Uterine Body Neoplasms. The initial draft was created after a thorough evaluation. Opinions from within and outside the Japan Society of Gynecologic Oncology (JSGO) were incorporated into the final draft. The guidelines were published after their approval by the JSGO. These guidelines were created in accordance with the principles of "Evidence-Based Medicine", considered to be the international standard for creating clinical practice guidelines. Searches were performed of data

I. Konishi  
Department of Obstetrics and Gynecology,  
Kyoto University School of Medicine, Kyoto, Japan

K. Ochiai  
Department of Obstetrics and Gynecology,  
Juntendo University School of Medicine, Tokyo, Japan

M. Mikami  
Department of Obstetrics and Gynecology, Tokai University  
School of Medicine, Isehara, Kanagawa, Japan

T. Sugiyama  
Department of Obstetrics and Gynecology,  
Iwate Medical University, Morioka, Iwate, Japan

M. Mukai  
Department of Diagnostic Pathology,  
Keio University Hospital, Tokyo, Japan

S. Sagae  
Department of Obstetrics and Gynecology,  
JR Sapporo Hospital, Sapporo, Japan

H. Hoshiai  
Department of Obstetrics and Gynecology, Kinki University  
School of Medicine, Osakasayama, Osaka, Japan

M. Ohmichi  
Department of Obstetrics and Gynecology,  
Osaka Medical College, Takatsuki, Osaka, Japan

H. Yoshikawa  
Department of Obstetrics and Gynecology,  
Graduate School of Comprehensive Human Science,  
University of Tsukuba, Tsukuba, Ibaraki, Japan

T. Iwasaka  
Department of Obstetrics and Gynecology,  
Saga Medical School, Saga, Japan

and literature published up until October 2008 and included Japanese and non-Japanese studies in Japan and overseas. The surgical staging criteria described in the 2009 edition were based on the surgical staging system developed in 1988 by the International Federation of Gynecology and Obstetrics.

Much of the evidence that formed the basis for the Japanese guidelines was obtained from clinical trials in Western countries. However, given the differences between practice in Japan and other countries, the consensus clinical practice in Japan took priority in the event of discrepancies. Wherever possible, high-level Japanese evidence was utilized to formulate these guidelines. Finally, these guidelines are not intended to restrict the use of treatments not mentioned in this text.

### Evidence levels and the grade of recommendation

The collected evidence was evaluated for quality using the criteria of the Japan Society of Clinical Oncology and its Formulation Committee of Clinical Practice Guidelines for the Use of Anticancer Agents (Table 1). The grades of the recommendations in our guidelines were also determined according to the Medical Information Network Distribution Service as shown in Table 2.

**Table 1** Evidence quality evaluation criteria (levels)

I	Evidence from meta-analyses of multiple randomized controlled trials
II	Evidence from at least one randomized controlled trial, or evidence from multiple well-designed controlled studies without randomization
III	Evidence obtained from at least one other type of well-designed quasi-experimental study, or evidence obtained from well-designed, non-experimental descriptive studies, for example comparative studies, correlation studies, and case studies
IV	Expert committee reports, or opinions and/or clinical experiences of respected authorities

**Table 2** Grades of recommendation

A	Can be strongly recommended that clinicians provide the intervention to eligible patients. There is evidence from at least one level I quality study to indicate efficacy
B	Recommended that clinicians provide to eligible patients. There is evidence from at least one level II quality study to support efficacy
C1	There is insufficient evidence to make a recommendation; however, clinicians may use their discretion to provide this intervention to eligible patients. There is evidence from more than one level III quality study suggesting efficacy
C2	There is insufficient evidence to recommend the intervention for routine practice
D	The intervention is not recommended as there is a possibility that its benefits are outweighed by its harm

### Algorithms

These guidelines contain the following nine algorithms:

1. Initial Treatment: Clinical Stages I and II (Fig. 1).
2. Initial Treatment: Clinical Stages III and IV (Fig. 2).
3. Postoperative Adjuvant Therapy for Endometrial Cancer (Fig. 3; Table 3).
4. Treatment of Recurrent Endometrial Cancer (Fig. 4).
5. Strategies for Fertility-Preserving Treatment: Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma of Grade 1 (Fig. 5).
6. Initial Treatment and Postoperative Adjuvant Therapy for Serous or Clear-Cell Adenocarcinoma (Fig. 6).
7. Treatment of Recurrent Serous or Clear-Cell Adenocarcinoma (Fig. 6).
8. Treatment for Carcinosarcoma (Fig. 7).
9. Treatment for Uterine Sarcoma (Leiomyosarcoma, Endometrial Stromal Sarcoma) (Fig. 8).

### Summary of recommendations

In general, each chapter consists of a clinical question (CQ), recommendations, background, objectives, explanations, and references. This article summarizes these guidelines in a question and answer format. Recommendations from each chapter are listed below under their respective chapter titles. References in each chapter are available through the JSGO web site (<http://www.jsgo.gr.jp/>).

#### Chapter 1: Overview of guidelines

#### Chapter 2: Initial treatment

**CQ01** Which surgical techniques for hysterectomy are recommended for clinical stage I?

Recommendations:

1. Abdominal total hysterectomy (extrafascial technique) is recommended (Grade B).
2. Modified radical (extended) hysterectomy is also an option (Grade C1).

**CQ02** Which surgical techniques of hysterectomy are recommended for clinical stage II?

Recommendations: It is advisable to employ either radical hysterectomy or modified radical hysterectomy for patients with clinically apparent cervical involvement (Grade C1).

**CQ03** What are the benefits of pelvic lymphadenectomy?

Recommendations: Pelvic lymphadenectomy is critical for accurate surgical staging, which has implications




Fig. 1 Initial treatment for clinical stages I and II. Staging is based on clinical findings. Radiotherapy or chemotherapy is performed for inoperable patients. CQ indicates a clinical question




Fig. 2 Initial treatment for clinical stage III–IV. Patients with extraperitoneal/hepatic lesions can present with symptoms such as hemorrhage. Accordingly, palliative total abdominal hysterectomy is sometimes performed

for prognosis. There are, however, no therapeutic benefits of pelvic lymphadenectomy demonstrated thus far (Grade C1).


CQ04 What are the benefits of para-aortic lymphadenectomy in addition to pelvic lymphadenectomy?

Recommendations: Para-aortic lymphadenectomy enables accurate surgical staging, although there still remain

controversies regarding therapeutic benefit of para-aortic lymphadenectomy (Grade C1).

CQ05 What are the clinical benefits of partial vaginectomy?

Recommendations: Partial vaginectomy might be performed to reduce vaginal stump recurrence, although the benefit of partial vaginectomy has not been demonstrated (Grade C1).



**Fig. 3** Postoperative adjuvant therapy for endometrial cancer (endometrioid adenocarcinoma). Patients with positive peritoneal cytology are classified as stage IIIa in the surgical staging. However, if there are no predictive factors associated with a poor prognosis other than positive peritoneal cytology, or there are no findings of extrauterine spread, it has been reported that positive peritoneal cytology is not a predictive factor associated with a poor prognosis. If there are

predictive factors associated with a poor prognosis other than positive peritoneal cytology or spread to an extrauterine site, in addition to positive peritoneal cytology, the appropriate postoperative treatment is recommended. Radiotherapy and chemotherapy are often performed as adjuvant therapy for the intermediate risk group. However, there is insufficient evidence for their utility. Therefore additional clinical trials need to be performed. See CQ17, CQ18, CQ19, and CQ21

**Table 3** Classification of postoperative recurrence risk of uterine body cancer

<b>Low-risk group</b>
Endometrioid adenocarcinoma G1 or G2 and ≤1/2 myometrial invasion
No cervical invasion
Negative peritoneal cytology
No venous or lymphatic invasion
No distant metastasis
<b>Intermediate-risk group</b>
Endometrioid adenocarcinoma G3 and ≤1/2 myometrial invasion
Endometrioid adenocarcinoma and >1/2 myometrial invasion
Cervical invasion
Positive peritoneal cytology (see CQ12)
Venous or lymphatic invasion
Serous adenocarcinoma, clear-cell adenocarcinoma, or undifferentiated carcinoma
No distant metastasis
<b>High-risk group</b>
Spread to the uterine adnexae, serosa, or cardinal ligament
Invasion of the vaginal wall
Pelvic or para-aortic lymph node metastasis
Vesical or rectal invasion
Peritoneal dissemination
Distant metastasis

Extracted from reference [6] (with some modifications)

**CQ06** Are young patients candidates for ovarian preservation?

**Recommendations:** Caution should be exercised with regard to ovarian preservation, even in young patients (Grade C1).

**CQ07** In the surgical staging guidelines, inguinal lymph node metastases are considered for staging. Is an inguinal lymph node biopsy necessary?

**Recommendations:**

1. If an enlarged inguinal lymph node is detected in preoperative imaging, for example CT scanning, then biopsy is recommended to determine the surgical stage (Grade B).
2. If an enlarged inguinal lymph node is not detected, the benefits of biopsy are not evident. Therefore, routine inguinal lymph node biopsy is not recommended (Grade C2).




Fig. 4 Treatment of recurrent endometrial cancer. Surgical resection is sometimes performed for patients with multiple resectable metastases




Fig. 5 Strategies for fertility preservation in the treatment of atypical endometrial hyperplasia and well differentiated endometrial adenocarcinoma (G1)

CQ08 Is omentectomy necessary?

Recommendations: Omentectomy is useful to determine metastatic involvement in the setting of visible macroscopic intrapelvic or peritoneal dissemination, or if the pathological diagnosis is serous adenocarcinoma or clear-cell adenocarcinoma (Grade C1).

CQ09 Is preoperative diagnostic imaging necessary for surgical planning?

Recommendations:

1. It is advisable to evaluate for myometrial invasion and cervical invasion by preoperative MRI (Grade C1).




Fig. 6 Initial treatment and postoperative adjuvant therapy for serous/clear-cell adenocarcinoma and recurrent tumors




Fig. 7 Treatment for carcinosarcoma. Radiotherapy or chemotherapy is performed for inoperable patients with advanced disease

2. It is advisable to evaluate for lymph node metastases or distant metastases by preoperative imaging (Grade C1).

CQ10 Is intraoperative frozen-section diagnosis useful for the determination of histological type, degree of differentiation, and degree of myometrial invasion?

Recommendations: Intraoperative frozen-section diagnosis is useful for predicting high-risk disease for which pelvic and para-aortic lymphadenectomy or omentectomy would be appropriate (Grade C1).


CQ11 Should intraoperative frozen-section diagnosis be performed to detect lymph node metastases?

Recommendations: There is insufficient evidence to recommend modification of the surgical technique on the basis of the status of lymph node metastases assessed with intraoperative frozen-section. It is not recommended in daily practice (Grade C2).

CQ12 Can lymphadenectomy be omitted if a sentinel node biopsy is performed?

Recommendations: There is insufficient evidence to omit retroperitoneal lymphadenectomy on the basis of sentinel lymph node status. It is not recommended in daily practice (Grade C2).





**Fig. 8** Treatment for uterine sarcoma (leiomyosarcoma, endometrial stromal sarcoma). *LGESS* Low-grade endometrial stromal sarcoma, *HGESS* high-grade endometrial stromal sarcoma, *LMS* uterine leiomyosarcoma

**CQ13** Should peritoneal cytology be used to determine the surgical approach?

**Recommendations:** Positive peritoneal cytology is not an independent factor for poor prognosis, if it is an isolated finding during complete surgical staging and if there is no other evidence of extrauterine spread. Peritoneal cytology is, however, a required component of complete surgical staging in accordance with the recent General Rules for Clinical and Pathological Management of Uterine Corpus Cancer (2nd edition) in Japan (Grade A).

**CQ14** Is rapid intraoperative peritoneal cytology necessary for determination of the surgical technique?

**Recommendations:** There is insufficient evidence to support basing the surgical technique on the results of rapid intraoperative peritoneal cytology. It is not recommended in daily practice (Grade C2).

**CQ15** Will endoscopic surgery become the standard surgical technique?

**Recommendations:** At present, endoscopic surgery has not been established as the standard surgical technique, and is not recommended in daily practice (Grade C2).

**CQ16** Is radiotherapy recommended for patients who are poor surgical candidates?

**Recommendations:** Radiotherapy is recommended for these patients (Grade B).

**Chapter 3: Postoperative adjuvant therapy**

**I. Radiotherapy**

**CQ17** What are the indications for postoperative whole-pelvis external-beam irradiation?

**Recommendations:**

1. Postoperative whole-pelvis external-beam irradiation might be useful for patients with multiple risk factors for recurrence (Grade C1).
2. Postoperative whole-pelvis external-beam irradiation is not recommended for patients without risk factors for recurrence (Grade D).

**CQ18** Is postoperative vaginal brachytherapy useful?

**Recommendations:** Postoperative vaginal brachytherapy might be performed to reduce the vaginal recurrence rate, although it is unclear whether it prolongs overall survival (Grade C1).

**CQ19** Is postoperative irradiation of the para-aortic lymph node region and whole abdominal irradiation useful?

**Recommendations:**

1. Postoperative irradiation of the para-aortic lymph node region may be considered, although there is insufficient clinical evidence to demonstrate its benefits (Grade C1).
2. Postoperative whole abdominal irradiation is not clearly beneficial, and is not recommended in daily practice (Grade C2).

**CQ20** Are there contraindications for postoperative radiotherapy?

**Recommendations:**

1. Postoperative radiotherapy is contraindicated in patients with previous radiotherapy to the pelvis (Grade A).
2. Postoperative radiotherapy may be considered for patients with concurrent rheumatic diseases or concurrent inflammatory bowel diseases if the patients are

deemed to be at high risk of recurrence. These patients must be closely monitored for adverse radiation effects (Grade B).

## II. Chemotherapy and hormone therapy

**CQ21** Has the efficacy of postoperative adjuvant chemotherapy been established?

Recommendations:

1. Postoperative adjuvant chemotherapy is recommended for high-risk patients with residual tumor smaller than 2 cm (Grade B).
2. Postoperative adjuvant chemotherapy may improve the prognosis for intermediate-risk patients (Grade C1).
3. Postoperative adjuvant chemotherapy is not recommended for low-risk patients (Grade D).

**CQ22** Which drugs are recommended for postoperative adjuvant chemotherapy?

Recommendations:

1. Regimens including anthracyclines and platinum-based drugs are recommended (Grade B).
2. Taxanes may also be used in combination with the above, although there is insufficient evidence to recommend this (Grade C1).

**CQ23** Is hormone therapy recommended as a postoperative adjuvant therapy?

Recommendations: Postoperative high-dose progesterone therapy is not recommended for patients with a low risk of recurrence (Grade D).

## Chapter 4: Post-treatment follow-up

**CQ24** What intervals are recommended for post-treatment follow-up?

Recommendations: Standard intervals between routine follow-up appointments are as shown below (Grade C1):

1. Every 1–3 months for the first 1–3 years after treatment;
2. Every 6 months for the fourth and fifth years after treatment;
3. Annually from the sixth year after treatment.

**CQ25** Should serum tumor markers be measured in post-treatment follow-up?

Recommendations: CA-125 or CA19-9 may be measured in post-treatment follow-up, although the merits of measuring tumor markers have not been established (Grade C1).

**CQ26** Are a pelvic examination and vaginal vault smears useful in post-treatment follow-up?

Recommendations:

1. Because pelvic recurrences account for 30–65% of recurrences, pelvic examination is useful (Grade B).
2. Vaginal vault smears may be useful for detecting vaginal stump recurrences (Grade C1).

**CQ27** How often should chest X-rays and other diagnostic imaging methods be performed in post-treatment follow-up?

Recommendations:

1. It is advisable to perform a chest X-ray annually or biannually for early detection of recurrence (Grade C1).
2. Diagnostic imaging methods other than chest X-ray are useful as a method to confirm recurrence which is clinically suspected (Grade B).

## Chapter 5: Treatment of advanced and recurrent cancer

**CQ28** What is the indication for surgery for clinical stages III and IVa?

Recommendations: It is advisable to choose surgery whenever a hysterectomy and cytoreduction are possible (Grade C1).

**CQ29** What are the therapeutic benefits of cytoreductive surgery for patients with macroscopic extrapelvic and intra-abdominal spread?

Recommendations: The prognosis may be improved by cytoreductive surgery (Grade C1).

**CQ30** Are neoadjuvant chemotherapy and preoperative radiotherapy useful for advanced cancer?

Recommendations:

1. The benefits of preoperative chemotherapy are not evident; it is, therefore, not recommended for routine practice (Grade C2).
2. Preoperative radiotherapy may be used for patients with cervical invasion and enlargement; however, it is not commonly practiced in Japan (Grade C2).

**CQ31** What are the indications for surgery for recurrent cancer?

Recommendations:

1. Surgical resection is considered for all operable patients without obvious distant metastasis (Grade C1).
2. Partial resection of the lung is considered for patients with lung metastases smaller than 4 cm (Grade C1).

**CQ32** Is chemotherapy useful for advanced and recurrent cancer?

**Recommendations:** Chemotherapy is useful for patients with incompletely resected advanced cancer (stages III and IVa), distant metastasis (stage IVb), or recurrent cancer (Grade B).

**CQ33** Which regimens are recommended for chemotherapy in advanced and recurrent cancer?

**Recommendations:** Platinum-based drugs in combination with anthracyclines or taxanes are recommended (Grade B).

**CQ34** Is radiotherapy useful for recurrent and inoperable advanced cancer?

**Recommendations:**

1. Radiotherapy is useful for patients with recurrence at the vaginal cuff (Grade B).
2. Radiotherapy is a palliative option for advanced and recurrent cancer (Grade C1).

**CQ35** Is progesterone therapy useful for advanced and recurrent cancer?

**Recommendations:** Progesterone therapy is useful for patients with well-differentiated endometrioid adenocarcinoma and advanced or recurrent cancer with positive progesterone receptors (Grade B).

#### Chapter 6: Fertility-preserving treatment

**CQ36** Is progesterone therapy useful for patients with well-differentiated endometrioid adenocarcinoma who desire fertility preservation?

**Recommendations:** Progesterone therapy might be useful as a fertility-preserving treatment for patients with well-differentiated endometrioid adenocarcinoma suspected to be confined to the endometrium (Grade C1).

**CQ37** What treatments are recommended for recurrent cases of well-differentiated endometrioid adenocarcinoma after fertility preservation therapy?

**Recommendations:**

1. The effectiveness of retreatment with progesterone has not been established in patients with recurrent disease. Retreatment with progesterone is not recommended for routine practice (Grade C2).
2. Total hysterectomy is recommended for patients with recurrent disease, an incomplete response, or progressive disease (Grade B).

**CQ38** What are the adverse effects of progesterone therapy and their associated risk factors?

**Recommendations:** Thrombosis is a serious adverse reaction associated with progesterone therapy. Use of progesterone should be avoided in patients with a high risk of thrombosis (Grade D).

**CQ39** Is ovulation induction permissible in patients who have preserved fertility?

**Recommendations:** Induction of ovulation is not contraindicated, because there is no evidence that it negatively affects prognosis (Grade C1).

**CQ40** What are suitable follow-up periods and examinations?

**Recommendations:** It is advisable to perform a complete endometrial curettage and transvaginal ultrasonography every 3 months after completion of medroxyprogesterone acetate (MPA) therapy (Grade C1).

#### Chapter 7: Atypical endometrial hyperplasia

**CQ41** What are the benefits of progesterone therapy if fertility-preserving treatment is used for atypical endometrial hyperplasia?

**Recommendations:** Progesterone therapy is useful in patients who desire fertility preservation. In this setting, it is advisable to perform a complete endometrial curettage and transvaginal ultrasonography at intervals of 3–6 months (Grade C1).

**CQ42** Is endometrial biopsy alone sufficient for diagnosing atypical endometrial hyperplasia?

**Recommendations:** Even if endometrial atypical hyperplasia is diagnosed by endometrial biopsy, a complete endometrial curettage is recommended because of the high rate of concomitant cancer (Grade A).

#### Chapter 8: Non endometrioid types

**CQ43** What surgical technique is recommended for serous adenocarcinoma and clear-cell adenocarcinoma?

**Recommendations:**

1. Total hysterectomy with bilateral salpingo-oophorectomy is employed to determine the accurate surgical stage (Grade B).
2. It is advisable to perform pelvic and para aortic lymphadenectomy/lymph nodes biopsy (Grade C1).
3. Omentectomy is useful to assess spread (Grade C1).

**CQ44** What postoperative adjuvant therapy is recommended for surgical stage I and II serous and clear-cell adenocarcinoma?

**Recommendations:** It is advisable to perform chemotherapy or radiotherapy for surgical stage Ib and II serous adenocarcinoma (Grade C1). There is insufficient evidence to support the routine use of adjuvant therapy for clear-cell adenocarcinoma.

**CQ45** What treatments are recommended in advanced or recurrent cases of serous adenocarcinoma or clear-cell adenocarcinoma?

**Recommendations:**

1. For advanced cases, it is advisable to attempt to achieve optimum cytoreduction in addition to total hysterectomy (Grade C1).
2. The effectiveness of chemotherapy for advanced or recurrent serous adenocarcinoma is equivalent to, if not superior to, that of radiotherapy (Grade C1).

#### Chapter 9: Carcinosarcoma and sarcoma

**CQ46** What surgical techniques are recommended for uterine carcinosarcoma?

**Recommendations:**

1. Total hysterectomy with bilateral salpingo-oophorectomy is the standard method (Grade B).
2. Radical hysterectomy or modified radical hysterectomy is considered for patients with cervical stromal invasion (Grade C1).
3. Pelvic and para-aortic lymphadenectomy/lymph node biopsy is required for accurate surgical staging, although no therapeutic benefits have been established (Grade C1).

**CQ47** What postoperative adjuvant therapy is recommended for uterine carcinosarcoma?

**Recommendations:**

1. If postoperative chemotherapy is selected, regimens which include ifosfamide, platinum-based drugs, and paclitaxel are preferable (Grade C1).
2. Radiotherapy (whole-pelvis external-beam irradiation) may also be considered (Grade C1).

**CQ48** What treatments are recommended in advanced and recurrent uterine carcinosarcoma?

**Recommendations:**

1. Regimens including ifosfamide, platinum-based drugs, and paclitaxel are advisable for chemotherapy in advanced or recurrent cases (Grade C1).
2. Surgical resection may be performed to treat intraperitoneal dissemination and recurrence, or distance metastasis (Grade C1).

**CQ49** What surgical techniques and postoperative adjuvant therapy are recommended for uterine leiomyosarcoma?

**Recommendations:**

1. Complete extraction including a total hysterectomy with bilateral salpingo-oophorectomy is recommended (Grade B).
2. Chemotherapy is considered if postoperative adjuvant therapy is needed (Grade C1).
3. Postoperative radiation is less efficacious, and therefore is not recommended in routine practice (Grade C2).

**CQ50** What surgical techniques and postoperative adjuvant therapy are recommended for endometrial stromal sarcoma (ESS)?

**Recommendations:**

1. Complete extraction including a total hysterectomy with bilateral salpingo-oophorectomy is recommended (Grade B).
2. For high grade ESS, pelvic and para-aortic lymphadenectomy/lymph node biopsy or cytoreductive surgery should be considered (Grade C1).
3. For early stage low grade ESS, follow-up without postoperative adjuvant therapy is recommended (Grade B).
4. For high grade ESS, adjuvant chemotherapy is advisable (Grade C1).

**CQ51** What treatments are recommended for unresectable or recurrent ESS/leiomyosarcoma?

**Recommendations:**

1. Recurrences should be treated surgically if the tumor is resectable (Grade C1).
2. Chemotherapy may be considered (Grade C1).
3. Hormonal therapy may be considered for low-grade ESS (Grade C1).
4. Radiation therapy for the purpose of palliative care may be considered (Grade C1).

**Acknowledgments** We thank the Japan Society of Obstetrics and Gynecology, Japan Association of Obstetricians and Gynecologists, Japanese Gynecologic Oncology Group, and Japan Society of Clinical Oncology for their comments and contributions throughout the project. We also thank Dr Ryoichi Nagatomi (Department of Medicine and Science in Sports and Exercise, Tohoku University) for his pointed advice in the translation.

**Conflict of interest** M. Mikami received a research funding from Mitsubishi Chemical Group Science and Technology Research Center, Inc., and N. Katsumata has received honoraria from Sanofi-aventis, Kyowa Hakko Kirin, Chugai Pharmaceutical, Yakult Honsha,